rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Harish Shantharam

Chief Financial Officer

Company insider

Files Form 4 as: Chief Financial Officer, ALX Oncology Holdings; Chief Financial Officer, CymaBay Therapeutics.

Every Form 4 they filed

In numbers

Trades disclosed
12
Buys
1
Sells
0
Bought
$59K
Sold
$0
Companies
2
Companies where not an officer
0
First trade
22 May 2023
Last trade
26 Jan 2026
Last filed
28 Jan 2026

Companies traded

Where they are an officer
ALXO ALX Oncology HoldingsOfficer · Biotechnology · last 26 Jan 20261 buy · 0 sells
CymaBay TherapeuticsOfficer · last 22 Mar 20240 buys · 0 sells

Activity over time

1 Aug 2025 – 1 Oct 2026
01Aug 25Dec 25Mar 26Jul 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
26 Jan 2026filed 28 Jan 2026ALXO ALX Oncology Holdingsoption or derivative · BiotechnologySEC FORM 4 Code A—303,000 at $0.00filing
26 Jan 2026filed 28 Jan 2026ALXO ALX Oncology Holdingsoption or derivative · BiotechnologySEC FORM 4 Code A—303,000 at $0.00filing
14 Oct 2025filed 16 Oct 2025ALXO ALX Oncology Holdingsoption or derivative · BiotechnologySEC FORM 4 Code A—198,750 at $0.00filing
18 Aug 2025filed 20 Aug 2025ALXO ALX Oncology HoldingsBiotechnologySEC FORM 4 Bought$59K75,000 at $0.78filing
11 Apr 2025filed 15 Apr 2025ALXO ALX Oncology Holdingsoption or derivative · BiotechnologySEC FORM 4 Code A—125,000 at $0.00filing
21 Jan 2025filed 23 Jan 2025ALXO ALX Oncology Holdingsoption or derivative · BiotechnologySEC FORM 4 Code A—600,000 at $0.00filing
22 Mar 2024filed 22 Mar 2024CymaBay Therapeuticsoption or derivativeSEC FORM 4 Code D—360,000filing
22 Mar 2024filed 22 Mar 2024CymaBay Therapeuticsoption or derivativeSEC FORM 4 Code D—74,750filing
22 Mar 2024filed 22 Mar 2024CymaBay TherapeuticsSEC FORM 4 Code D—20,125filing
24 Jan 2024filed 26 Jan 2024CymaBay Therapeuticsoption or derivativeSEC FORM 4 Code A—74,750 at $0.00filing
24 Jan 2024filed 26 Jan 2024CymaBay TherapeuticsSEC FORM 4 Code A—20,125 at $0.00filing
22 May 2023filed 22 May 2023CymaBay Therapeuticsoption or derivativeSEC FORM 4 Code A—360,000 at $0.00filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Health Care1

Buys in green, sells in red, by the company’s sector.

Related people

Jason LettmannChief Executive Officer · Chief Executive Officer at Alx Oncology Holdings, filing Form 4 there in the last year
Shelly WongSVP, Finance and CAO · SVP, Finance and CAO at Alx Oncology Holdings, filing Form 4 there in the last year
Barbara KlenckeDirector · Chief Medical Officer at Alx Oncology Holdings, filing Form 4 there in the last year
Jeff E. KnightChief Dev & Operating Officer · Chief Dev & Operating Officer at Alx Oncology Holdings, filing Form 4 there in the last year
Corey S. GoodmanDirector and 10% owner · Director and 10% owner at Alx Oncology Holdings, filing Form 4 there in the last year